Stuart J. Wong
Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Stuart J. Wong

Oncology | Hematology
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
32 Years of Experience
Advanced in Primitive Neuroectodermal Tumor (PNET)
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stuart Wong is an Oncologist and a Hematologist in Milwaukee, Wisconsin. Dr. Wong has been practicing medicine for over 32 years and is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Oral Squamous Cell Carcinoma, and Primitive Neuroectodermal Tumor (PNET). Dr. Wong is currently accepting new patients.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
Froedtert Memorial Lutheran Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

THE MEDICAL COLLEGE OF WISCONSIN INC
8701 Watertown Plank Rd, Room 4041 Mfrc, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Enrollment Status: Recruiting
Publish Date: December 24, 2024
Intervention Type: Radiation, Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Docetaxel
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: HB-201, HB-202
Study Phase: Phase 1/Phase 2
A Phase 0 Trial of HB-201 for Subjects With Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or With Locally Advanced Cervical Cancer Treated With Chemotherapy and Radiation
A Phase 0 Trial of HB-201 for Subjects With Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or With Locally Advanced Cervical Cancer Treated With Chemotherapy and Radiation
Enrollment Status: Terminated
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drug: HB-201
Study Phase: Early Phase 1
Inhibition of Oral Tumorigenesis by Antitumor B
Inhibition of Oral Tumorigenesis by Antitumor B
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drug: Anti-tumor B
Study Phase: Early Phase 1
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Efatutazone, Paclitaxel
Study Phase: Phase 2
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Biological, Radiation
Study Drug: Nivolumab
Study Phase: Phase 2
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

67 Total Publications

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2025
Similar Doctors
Laura P. Mcgartland
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Laura P. Mcgartland
Hematology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Laura P. Mcgartland
Hematology | Oncology

Aurora Cancer Care

2801 W Kinnickinnic River Pkwy, Ste 980, 
Milwaukee, WI 
 (5.2 miles away)
414-384-5111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Laura Mcgartland is a Hematologist and an Oncologist in Milwaukee, Wisconsin. Dr. Mcgartland is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Pleuropulmonary Blastoma, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Thomas A. Hensing
Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Thomas A. Hensing
Oncology

Endeavor Health Medical Group

777 Park W Ave, 
Highland Park, IL 
 (60.0 miles away)
847-432-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Hensing is an Oncologist in Highland Park, Illinois. Dr. Hensing is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Hensing is currently accepting new patients.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Narendrakumar A. Kapadia
Oncology | Hematology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Narendrakumar A. Kapadia
Oncology | Hematology
Cancer Treatment Centers Of America, 202 S. Greenleaf Ave Suite E, 
Gurnee, IL 
 (46.5 miles away)
800-322-9183
Languages Spoken:
English
See accepted insurances

Narendrakumar Kapadia is an Oncologist and a Hematologist in Gurnee, Illinois. Dr. Kapadia is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Thrombocytopenia, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, and Familial Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wong's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile